PH12019500711A1 - Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy - Google Patents

Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

Info

Publication number
PH12019500711A1
PH12019500711A1 PH12019500711A PH12019500711A PH12019500711A1 PH 12019500711 A1 PH12019500711 A1 PH 12019500711A1 PH 12019500711 A PH12019500711 A PH 12019500711A PH 12019500711 A PH12019500711 A PH 12019500711A PH 12019500711 A1 PH12019500711 A1 PH 12019500711A1
Authority
PH
Philippines
Prior art keywords
nephropathy
immunoglobulin
methods
human subject
subject suffering
Prior art date
Application number
PH12019500711A
Other languages
English (en)
Inventor
Nigel John Brunskill
Gregory A Demopulos
Tom Dudler
Hans-Wilhelm Schwaeble
Original Assignee
Omeros Corp
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/399,524 external-priority patent/US10736960B2/en
Priority claimed from US15/470,647 external-priority patent/US20170253667A1/en
Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp
Publication of PH12019500711A1 publication Critical patent/PH12019500711A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Environmental Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Husbandry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH12019500711A 2016-10-13 2019-04-01 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy PH12019500711A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662407979P 2016-10-13 2016-10-13
US15/399,524 US10736960B2 (en) 2016-01-05 2017-01-05 Methods for inhibiting fibrosis in a subject in need thereof
US15/470,647 US20170253667A1 (en) 2016-01-05 2017-03-27 Methods for inhibiting fibrosis in a subject in need thereof
US201762527926P 2017-06-30 2017-06-30
PCT/US2017/056386 WO2018071701A1 (en) 2016-10-13 2017-10-12 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

Publications (1)

Publication Number Publication Date
PH12019500711A1 true PH12019500711A1 (en) 2019-11-18

Family

ID=61906454

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019500711A PH12019500711A1 (en) 2016-10-13 2019-04-01 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

Country Status (18)

Country Link
EP (1) EP3525798A4 (zh)
JP (1) JP6893554B2 (zh)
KR (1) KR102348939B1 (zh)
CN (2) CN110177557A (zh)
AU (1) AU2017342428B2 (zh)
BR (1) BR112019007426A2 (zh)
CA (2) CA3210384A1 (zh)
CL (2) CL2019000909A1 (zh)
GE (1) GEP20247587B (zh)
IL (1) IL265981A (zh)
JO (1) JOP20190068A1 (zh)
MA (1) MA46541A (zh)
MX (1) MX2019004074A (zh)
PH (1) PH12019500711A1 (zh)
SG (1) SG11201902941UA (zh)
UA (1) UA126908C2 (zh)
WO (1) WO2018071701A1 (zh)
ZA (1) ZA201902933B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419860A (zh) * 2020-03-19 2020-07-17 长春市儿童医院 一种肾小球分叶状肾病造模方法
CN115215937B (zh) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
CN117016486B (zh) * 2023-07-20 2024-05-14 上海澎立生技医药研究有限公司 一种IgA肾病合并膜性肾病的动物模型构建方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2374819T1 (sl) * 2003-05-12 2017-09-29 Helion Biotech Aps Protitelesa proteina MASP-2
US20140056873A1 (en) * 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7626730B2 (en) 2006-03-31 2009-12-01 Eastman Kodak Company Method of making a multilevel halftone screen
CN106390117A (zh) * 2009-10-16 2017-02-15 奥默罗斯公司 通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法
WO2012100262A1 (en) * 2011-01-21 2012-07-26 Fibrogen, Inc. Therapeutic method using anti - ctgf antibody
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2694108B1 (en) * 2011-04-08 2018-06-06 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
KR102024016B1 (ko) * 2011-05-04 2019-11-04 오메로스 코포레이션 Masp-2 의존적 보체 활성화를 억제하는 조성물
EP2968546B1 (en) * 2013-03-15 2023-09-20 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
JP2016539919A (ja) * 2013-10-17 2016-12-22 オメロス コーポレーション Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法
IL294411A (en) * 2016-01-05 2022-08-01 Omeros Corp masp-2 suppressors for use in suppressing fibrosis
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق

Also Published As

Publication number Publication date
EP3525798A1 (en) 2019-08-21
GEP20247587B (en) 2024-01-25
JP2019534271A (ja) 2019-11-28
CA3210384A1 (en) 2018-04-19
JP6893554B2 (ja) 2021-06-23
IL265981A (en) 2019-06-30
EP3525798A4 (en) 2020-07-08
NZ753260A (en) 2021-11-26
SG11201902941UA (en) 2019-05-30
CA3039927C (en) 2023-10-10
CA3039927A1 (en) 2018-04-19
MA46541A (fr) 2019-08-21
KR102348939B1 (ko) 2022-01-12
CL2019000909A1 (es) 2019-06-14
CL2019003485A1 (es) 2020-04-13
UA126908C2 (uk) 2023-02-22
BR112019007426A2 (pt) 2019-07-02
AU2017342428A1 (en) 2019-05-23
CN110177557A (zh) 2019-08-27
AU2017342428B2 (en) 2021-02-04
MX2019004074A (es) 2019-06-10
KR20190063475A (ko) 2019-06-07
ZA201902933B (en) 2023-05-31
JOP20190068A1 (ar) 2019-04-01
WO2018071701A1 (en) 2018-04-19
CN116726163A (zh) 2023-09-12

Similar Documents

Publication Publication Date Title
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
NZ738008A (en) Tigit-binding agents and uses thereof
MX2019013072A (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
MX2023007754A (es) Una composicion que comprende un anticuerpo inhibidor de masp-2 para su uso en el tratamiento de la nefropatia por inmunoglobulina a (igan) dependiente de esteroides.
NZ727020A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
MD3549592T2 (ro) Compoziții care conţin tulpini bacteriene
SA518390944B1 (ar) أجسام مضادة لمثبط مسار عامل نسيج واستخداماتها
CY1121806T1 (el) Ιμιδαζοπυραζινονες ως αναστολεις pde1
WO2014124334A3 (en) Transthyretin antibodies and uses thereof
BR112017023579A2 (pt) combinação de um anticorpo cd30xcd16 com um antagonista de pd-1 para terapia
PH12018500578A1 (en) Methods of treating inflammatory diseases
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
PH12019500711A1 (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
MX2018008302A (es) Anticuerpo antigrupo de diferenciacion 9 (anti-cd9) terapeutico.
EP4273165A3 (en) Interferon beta antibodies and uses thereof
PH12018500100A1 (en) Antibodies that bind to sortilin and inhibit the binding of progranulin
CY1122784T1 (el) Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
DK3630177T3 (da) Behandlingsparadigme til et anti-cd19-antistof og venetoclax-kombinationsbehandling
EA201990903A1 (ru) Способ уменьшения протеинурии у человека, страдающего от иммуноглобулин а нефропатии
MX2018004228A (es) Anticuerpo que se une especificamente a erbb3 y uso de este.
GB201800986D0 (en) Second Alzheimers treatment
EA202090453A3 (ru) Антитела к cd40
EP3385282C0 (en) MONOCLONAL ANTIBODIES AGAINST BAMBI AND USE TO TREAT INFLAMMATORY DISEASES